pathfinder临床试验项目概览:N8-GP在A型血友病患者中的长期疗效与安全性
N8-GP(turoctocog alfa pegol,Esperoct®)是一种用于A型血友病预防和按需治疗的延长半衰期FVIII分子。pathfinder临床试验项目自2010年pathfinder1试验开始,旨在评估N8-GP在儿童、青少年和成人中的长期疗效与安全性;关键性pathfinder2(青少年和成人)和pathfinder5(儿童)试验于2018年底完成,pathfinder3试验(评估大手术期间的安全性和有效性)近期也已最终确定。本文概述了pathfinder临床开发项目,总结了已完成试验的关键数据,并展望了延长半衰期FVIII分子的未来及正在进行的pathfinder试验。
要点
- N8-GP是一种延长半衰期FVIII分子,用于A型血友病的预防和按需治疗。
- pathfinder项目自2010年启动,评估N8-GP在儿童、青少年和成人中的长期疗效与安全性。
- pathfinder2和pathfinder5试验于2018年底完成,pathfinder3试验评估大手术期间的安全性和有效性。
核心结论
- 本文概述了pathfinder临床开发项目并总结了已完成试验的关键数据,同时展望了延长半衰期FVIII分子在A型血友病治疗中的未来并描述了正在进行的pathfinder试验。
研究设计与样本
- pathfinder临床试验项目于2010年以pathfinder1试验启动,旨在评估N8-GP在儿童、青少年和成人中的长期疗效与安全性;关键性pathfinder2(青少年和成人)和pathfinder5(儿童)试验于2018年底完成,pathfinder3试验(评估大手术期间的安全性和有效性)近期也已最终确定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
N8-GP (turoctocog alfa pegol, Esperoct® ; Novo Nordisk A/S, Bagsvaerd, Denmark) is a state-of-the-art, extended half-life factor VIII (FVIII) molecule used for prophylactic and on-demand treatment of patients with hemophilia A. The pathfinder clinical trial program, which began with the pathfinder1 trial in 2010, was developed to assess the long-term efficacy and safety of N8-GP in children, adolescents, and adults. The pivotal pathfinder2 (adolescents and adults) and pathfinder5 (children) trials were completed in late 2018, and comprehensive analyses of the end-of-trial results are published together with this article as part of an N8-GP Supplement. Furthermore, results from the pathfinder3 trial, which was designed to evaluate the safety and efficacy of N8-GP during major surgery, have also recently been finalized. Here, we provide an overview of the pathfinder clinical development program and summarize key data from the completed pathfinder trials. We also provide perspectives on the future of extended half-life FVIII molecules in the treatment of patients with hemophilia A and describe currently ongoing pathfinder trials.
引用
- Matsushita T, Mangles S. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A. J Thromb Haemost. 2020. PMID: 32558236. doi:10.1111/jth.14958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。